Cases & Deals

  • Home
  • Practices
  • sanofi-aventis acquires TargeGen for $560 million

Share

sanofi-aventis acquires TargeGen for $560 million

July 2010

Clients sanofi-aventis S.A.

Jones Day advised sanofi-aventis S.A. in reaching a $560 million merger agreement with TargeGen Inc., a privately held US biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood disorders. In addition to M&A representation, Jones Day provided tax, benefits and IP advice regarding this transaction.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.